19-Nov-15 Thermo Fisher Scientific has announced the opening of a new GMP facility in Singapore. The new site is intended to meet growing demand for clinical supply services in the region. It will provide pharma and biotech companies with a one-stop service for clinical supplies – including GMP storage, labelling, packaging, comparator sourcing, handling, distribution and returns management. [image: Thermo Fisher Scientific]

13-Oct-15 As China's growing 40+ population suffers increasingly from lifestyle diseases such as cardiac problems and cancer, many of the wealthy among them will seek treatment in the US or Europe. And many more will spend some of their new found wealth on plastic surgery, dentistry or wellness programs in Korea or Southeast Asia. Chinese medical tourists spent USD10 bn in 2014, only 2.3% of the global total, suggesting that there is a huge potential for further growth in the market. What can hospitals and governments do to tap into this opportunity? [image: Travel Daily News]

18-Nov-15 According to the Malaysian Healthcare Travel Council, Malaysia attracted 880,000 medical tourists in 2014 and wants to boost these numbers by 10% in 2015 and eventually cross the 1 mn mark by 2016. The MHTC is now focusing more intensely on “halal health treatments” to entice medical travellers from Muslim countries, such as those in the Gulf Cooperation Council. [image: Global Health and Travel]

18Nov-15 Sri Lanka’s healthcare sector has experience an enormous boom in recent years and is fast becoming a global health destination offering some of the best medical treatments in the world. This is evident from the increasing percentage of foreign patients occupying beds in major city hospitals. Sri Lanka has a competitive advantage in its highly skilled and internationally trained doctors. [image: Mirror Business]

18-Nov-15 The Brazilian São Paulo Research Foundation (FAPESP) and UK pharmaceutical firm GlaxoSmithKline (GSK) announced that they will be working together on the creation of two clinical research centres at educational and R&D institutions in the state of São Paulo. This project will require BRL88 mn, of which the FAPESP and GSK will share BRL35 mn. [image: GSK]